Comparative Study of Oral Cyclophosphamide and Mycophenolate mofetil in Childhood Nephrotic Syndrome
Not Applicable
- Conditions
- Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes
- Registration Number
- CTRI/2021/06/034421
- Lead Sponsor
- GURDEEP SINGH DHOORIA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children with Frequent Relapsing Steroid Dependent Nephrotic Syndrome
Exclusion Criteria
1. Congenital Nephrotic Syndrome
2. Steroid Resistant Nephrotic Syndrome
3. Patients with an estimated glomerular filtration rate ( <60 ml/min
per 1.73 m2
4. Known secondary causes including systemic lupus, Henoch
Schonlein purpura, IgA nephropathy or chronic infection (tuberculosis, HIV, hepatitis B or C.
5. Prior therapy with MMF, cyclosporine, tacrolimus, or cyclophosphamide in the past 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method